Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Use of proton pump inhibitors (PPIs) is associated with community-acquired pneumonia (CAP), an association which may be confounded by unobserved patient and prescriber characteristics.
We assessed for confounding in the association between PPI use and CAP by using a ‘falsification approach,’ which estimated whether PPI use is also implausibly associated with other common medical conditions for which no known pathophysiologic link exists.
Retrospective claims-based cohort study.
Six private U.S. health plans.
Individuals who filled at least one prescription for a PPI (N = 26,436) and those who never did (N = 28,054) over 11 years.
Multivariate linear regression of the association between a filled prescription for a PPI and a diagnosis of CAP in each 3-month quarter. In falsification analyses, we tested for implausible associations between PPI use in each quarter and rates of osteoarthritis, chest pain, urinary tract infection (UTI), deep venous thrombosis (DVT), skin infection, and rheumatoid arthritis. Independent variables included an indicator for whether a prescription for a PPI was filled in a given quarter, and quarterly indicators for various co-morbidities, age, income, geographic location, and marital status.
Compared to nonusers, those ever using a PPI had higher adjusted rates of CAP in quarters in which no prescription was filled (68 vs. 61 cases per 10,000 persons, p < 0.001). Similar associations were noted for all conditions (e.g. chest pain, 336 vs. 282 cases, p < 0.001; UTI, 151 vs. 139 cases, p < 0.001). Among those ever using a PPI, quarters in which a prescription was filled were associated with higher adjusted rates of CAP (111 vs. 68 cases per 10,000, p < 0.001) and all other conditions (e.g. chest pain, 597 vs. 336 cases, p < 0.001; UTI, 186 vs. 151 cases, p < 0.001), compared to quarters in which no prescription was filled.
PPI use is associated with CAP, but also implausibly associated with common medical conditions. Observed associations between PPI use and CAP may be confounded.
- Laheij, RJ, Sturkenboom, MC, Hassing, RJ, Dieleman, J, Stricker, BH, Jansen, JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292: pp. 1955-1960 CrossRef
- Sarkar, M, Hennessy, S, Yang, YX (2008) Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149: pp. 391-398
- Gulmez, SE, Holm, A, Frederiksen, H, Jensen, TG, Pedersen, C, Hallas, J (2007) Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med 167: pp. 950-955 CrossRef
- Howden, CW, Hunt, RH (1987) Relationship between gastric secretion and infection. Gut 28: pp. 96-107 CrossRef
- Giannella, RA, Broitman, SA, Zamcheck, N (1973) Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 78: pp. 271-276
- Ruddell, WS, Axon, AT, Findlay, JM, Bartholomew, BA, Hill, MJ (1980) Effect of cimetidine on the gastric bacterial flora. Lancet 1: pp. 672-674
- IMS. Leading Therapy Classes in 2002 Global Pharmaceutical Sales. IMS World Review. Vol. 2010; 2010.
- Yang, YX, Metz, DC (2010) Safety of proton pump inhibitor exposure. Gastroenterology 139: pp. 1115-1127 CrossRef
- Logan, IC, Sumukadas, D, Witham, MD (2010) Gastric acid suppressants–too much of a good thing?. Age and ageing 39: pp. 410-411 CrossRef
- Lodato, F, Azzaroli, F, Turco, L (2010) Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 24: pp. 193-201 CrossRef
- Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med. 2010;152(7):418–25, W139-40.
- Popper KR. The Logic of Scientific Discovery Routledge; 2002.
- Heckman, JJ, Hotz, VJ (1989) Choosing among alternative nonexperimental methods for estimating the impact of social programs: the case of manpower training. J Am Stat Assoc 84: pp. 862-874 CrossRef
- Bertrand, M, Duflo, E, Mullainathan, S (2004) How much should We trust differences-in-differences estimates?. Q J Econ 119: pp. 249-275 CrossRef
- Joyce, GF, Escarce, JJ, Solomon, MD, Goldman, DP (2002) Employer drug benefit plans and spending on prescription drugs. JAMA 288: pp. 1733-1739 CrossRef
- Goldman, DP, Joyce, GF, Lawless, G, Crown, WH, Willey, V (2006) Benefit design and specialty drug use. Health Aff (Millwood) 25: pp. 1319-1331 CrossRef
- Goldman, DP, Joyce, GF, Escarce, JJ (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291: pp. 2344-2350 CrossRef
- Solomon, MD, Goldman, DP, Joyce, GF, Escarce, JJ (2009) Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med 169: pp. 740-748 CrossRef
- Foxman, B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113: pp. 5S-13S CrossRef
- Ellis Simonsen, SM, Orman, ER, Hatch, BE (2006) Cellulitis incidence in a defined population. Epidemiol Infect 134: pp. 293-299 CrossRef
- United States Department of H, Human Services. Centers for Disease C, Prevention. National Center for Health S. National Ambulatory Medical Care Survey, 2009. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]; 2011.
- Ware, JH, Dockery, DW, Louis, TA, Xu, XP, Ferris, BG, Speizer, FE (1990) Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 132: pp. 685-700
- Garcia Rodriguez, LA, Ruigomez, A (1997) Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?. Epidemiology 8: pp. 571-574 CrossRef
- Neal, KR, Scott, HM, Slack, RC, Logan, RF (1996) Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ 312: pp. 414-415 CrossRef
- Dial, S, Alrasadi, K, Manoukian, C, Huang, A, Menzies, D (2004) Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ 171: pp. 33-38 CrossRef
- Linsky, A, Gupta, K, Lawler, EV, Fonda, JR, Hermos, JA (2010) Proton pump inhibitors and risk for recurrent clostridium difficile infection. Arch Intern Med 170: pp. 772-778 CrossRef
- Yang, YX, Lewis, JD, Epstein, S, Metz, DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: pp. 2947-2953 CrossRef
- Christakis, NA, Fowler, JH (2007) The spread of obesity in a large social network over 32 years. N Engl J Med 357: pp. 370-379 CrossRef
- Cohen-Cole, E, Fletcher, JM (2008) Detecting implausible social network effects in acne, height, and headaches: longitudinal analysis. BMJ 337: pp. a2533 CrossRef
- Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia
Journal of General Internal Medicine
Volume 28, Issue 2 , pp 223-230
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- proton pump inhibitors
- falsification testing
- Industry Sectors
- Author Affiliations
- 1. Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA, 02115, USA
- 2. Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- 3. Department of Medicine, National Bureau of Economic Research, Cambridge, MA, USA
- 4. Department of Anesthesia, Stanford University Hospitals, Stanford, CA, 94305, USA
- 5. Leonard D. Schaeffer Center for Health Policy and 7 Economics, University of Southern California, 650 Childs Way, RGL 214, Los Angeles, CA, 90089, USA